Lundbeck beats 1st-qtr sales expectation

12 May 2020

Danish CNS specialist Lundbeck (LUND: CO) today posted first-quarter 2020 financials, noting that revenues reached 4,564 million Danish kroner ($661.3 million), a rise of 8% (+7% in local currencies), above an average of 4.34 billion kroner forecast by analysts in a Refinitiv Eikon poll. Key brands registered cumulative growth of 35%.

Core earnings before interest and taxes (EBIT) came in at 1,357 million kroner, down 4%. On a reported basis, EBIT was 338 million kroner, down 72%. Core earnings per share were 4.89 kroner, down 11%.

Lundbeck shares rose 2.75% to 253.80 kroner in early trading, but drifted back to 245.50 kroner by late morning

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK